Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4.81
9.49
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AUPH stock under the Base Case scenario is 11.9 USD. Compared to the current market price of 8.38 USD, Aurinia Pharmaceuticals Inc is Undervalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Aurinia Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AUPH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Aurinia Pharmaceuticals Inc
Balance Sheet Decomposition
Aurinia Pharmaceuticals Inc
Current Assets | 409.7m |
Cash & Short-Term Investments | 330.3m |
Receivables | 25.5m |
Other Current Assets | 53.8m |
Non-Current Assets | 113.9m |
Long-Term Investments | 199k |
PP&E | 108.2m |
Intangibles | 4.6m |
Other Non-Current Assets | 867k |
Current Liabilities | 76.9m |
Accounts Payable | 8.4m |
Accrued Liabilities | 48.3m |
Other Current Liabilities | 20.1m |
Non-Current Liabilities | 82m |
Long-Term Debt | 64.9m |
Other Non-Current Liabilities | 17.1m |
Earnings Waterfall
Aurinia Pharmaceuticals Inc
Revenue
|
207.1m
USD
|
Cost of Revenue
|
-28.8m
USD
|
Gross Profit
|
178.3m
USD
|
Operating Expenses
|
-231.2m
USD
|
Operating Income
|
-52.9m
USD
|
Other Expenses
|
2.6m
USD
|
Net Income
|
-50.4m
USD
|
Free Cash Flow Analysis
Aurinia Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
AUPH Profitability Score
Profitability Due Diligence
Aurinia Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Aurinia Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
AUPH Solvency Score
Solvency Due Diligence
Aurinia Pharmaceuticals Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Aurinia Pharmaceuticals Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AUPH Price Targets Summary
Aurinia Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for AUPH is 9.97 USD with a low forecast of 6.06 USD and a high forecast of 13.65 USD.
Dividends
Current shareholder yield for AUPH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AUPH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia and currently employs 300 full-time employees. The company went IPO on 2001-07-16. The firm is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The firm has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The company also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.
Contact
IPO
Employees
Officers
The intrinsic value of one AUPH stock under the Base Case scenario is 11.9 USD.
Compared to the current market price of 8.38 USD, Aurinia Pharmaceuticals Inc is Undervalued by 30%.